Acumen Pharmaceuticals (ABOS) Investor Presentation - Slideshow

Financial Status - Acumen had approximately $225 million in cash, cash equivalents, and marketable securities as of December 31, 2021, which is expected to fund operations through 2025[5, 8, 93] - The company completed a Series B tranche with gross proceeds of $30 million and an IPO with gross proceeds of $184 million[7] - In FY 2021, R&D expenses were $123 million and G&A expenses were $73 million, resulting in a $196 million loss from operations[93] - The FY 2021 net loss was $101 million, including a non-cash expense of over $81 million[93] Clinical Development of ACU193 - ACU193 is a clinical-stage monoclonal antibody (mAb) designed to selectively target amyloid-beta oligomers (AβOs) for the treatment of early Alzheimer's disease (AD)[5, 38] - The INTERCEPT-AD trial, a Phase 1 clinical trial of ACU193 in patients with early AD, is ongoing, with topline results expected in 1H 2023[5, 9, 77, 88] - The primary outcomes of the INTERCEPT-AD trial are safety/ARIA-E, pharmacokinetics (PK), and target engagement[9, 88] - Acumen is developing a Phase 2/3 study design and planning for an FDA End of Phase 2 meeting[9] Alzheimer's Disease Market and Scientific Rationale - Alzheimer's disease (AD) represents a significant market driven by high unmet need, with direct healthcare costs estimated at $355 billion annually in 2021[5, 19] - Scientific consensus supports amyloid-beta oligomers (AβOs) as the most toxic form of amyloid-beta and a novel target for effective AD treatment[5, 11] - Recent anti-amyloid mAb results show a reduction in cognitive decline of approximately 11%-47% at ~18 months, with ARIA-E rates of approximately 10%-35%[25]